Abeona Insider Sales: Tax Strategy or Cash Crunch?
Insider sales of Abeona Therapeutics shares reveal tax‑driven cash moves, not a bearish trend, and suggest the company remains focused on its gene‑therapy pipeline.
3 minutes to read
Abeona Therapeutics Inc
Abeona CFO’s Tax‑Cover Sale Sparks Brief Insider‑Selling Wave, Not a Red Flag for Investors
Insider sales of Abeona shares were routine tax‑cover moves, not a downside signal – CFO Walter, CEO Vishwas and SVP O’Malley sold near‑fair‑value shares, leaving Abeona’s fundamentals solid and investors’ long‑term confidence intact.
3 minutes to read
Abeona Executives Bulk‑Buy Shares Amid Founder’s Small Sale: Insider Confidence Grows in Gene‑Therapy Startup
Explore Abeona’s insider trading: CEO buys amid stable shares, founder’s modest sale—signals confidence in gene‑therapy pipeline and potential long‑term value.
2 minutes to read
Abeona Executives Flip the Script: CEO, CFO, and Legal Officer Buy 600,000+ Shares in Bold Confidence Move
Insider buying surge at Abeona shows leadership confidence, not panic, amid clinical pipeline and partnership prospects—what it means for investors.
4 minutes to read